Axsome Therapeutics, Inc.
AXSM
$158.88
$1.010.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.03% | 63.22% | 72.13% | 61.95% | 66.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.03% | 63.22% | 72.13% | 61.95% | 66.04% |
| Cost of Revenue | 17.26% | 41.19% | 66.95% | 55.45% | 42.50% |
| Gross Profit | 69.67% | 65.15% | 72.66% | 62.55% | 68.74% |
| SG&A Expenses | 49.46% | 57.21% | 25.81% | 22.04% | 30.48% |
| Depreciation & Amortization | 0.00% | 0.06% | -0.06% | -1.07% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.62% | 35.05% | 19.51% | 23.14% | 42.50% |
| Operating Income | 41.55% | 28.79% | 40.94% | 19.24% | -11.92% |
| Income Before Tax | 62.41% | 26.89% | 38.33% | 13.08% | 24.40% |
| Income Tax Expenses | 405.88% | -- | -- | -- | 126.15% |
| Earnings from Continuing Operations | 61.88% | 26.89% | 39.54% | 13.08% | 24.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 61.88% | 26.89% | 39.54% | 13.08% | 24.06% |
| EBIT | 41.55% | 28.79% | 40.94% | 19.24% | -11.92% |
| EBITDA | 42.73% | 29.89% | 41.87% | 19.74% | -12.32% |
| EPS Basic | 63.45% | 29.64% | 41.82% | 15.71% | 25.96% |
| Normalized Basic EPS | 44.14% | 32.03% | 41.84% | 19.52% | -11.62% |
| EPS Diluted | 63.45% | 29.64% | 41.82% | 15.41% | 25.96% |
| Normalized Diluted EPS | 44.14% | 32.03% | 41.84% | 19.52% | -11.62% |
| Average Basic Shares Outstanding | 4.30% | 3.91% | 3.93% | 3.12% | 2.56% |
| Average Diluted Shares Outstanding | 4.30% | 3.91% | 3.93% | 3.12% | 2.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |